SCYNEXIS (SCYX) : Traders are bullish on SCYNEXIS (SCYX) as it has outperformed the S&P 500 by a wide margin of 18.47% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.61%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.17% in the last 1 week, and is up 16.07% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 12.3% and the 50-Day Moving Average is 34.23%.The 200 Day SMA reached 17.01% SCYNEXIS, Inc. is up 31.05% in the last 3-month period. Year-to-Date the stock performance stands at -47.67%.
SCYNEXIS (SCYX) : Currently there are 4 street experts covering SCYNEXIS (SCYX) stock. The most bullish and bearish price target for the stock is $16 and $8 respectively for the short term. The average price target of all the analysts comes to $12.25. The estimated standard deviation from the target is $3.86.
For the current week, the company shares have a recommendation consensus of Buy. SCYNEXIS (NASDAQ:SCYX): The stock opened at $2.96 and touched an intraday high of $3.3 on Friday. During the day, the stock corrected to an intraday low of $2.9, however, the bulls stepped in and pushed the price higher to close in the green at $3.25 with a gain of 11.30% for the day. The total traded volume for the day was 1,252,897. The stock had closed at $3.25 in the previous trading session.
SCYNEXIS, Inc. is a pharmaceutical company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It also provides contract research and development services primarily in the field of animal health. Its lead product candidate, SCY-078, is an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug resistant strains. In addition, the Company has additional compounds similar to SCY-078. The Company has developed a platform for cyclophilin inhibitors. Its cyclophilin inhibitor platform has two clinical stage compounds: SCY-635, which is a cyclophilin inhibitor for the treatment of dog dry eye and SCY-641, which is a cyclophilin inhibitor with activity similar to cyclosporine for the treatment of viral diseases in humans.